TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in endothelial progenitor cells colony forming units
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pharmacog battery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients colonized with MRSA
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Experiencing at Least One Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Discontinuing Study Drug Due to AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of adverse events following vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Hamilton Depression Rating Scale (HAMD or HDRS, 24 item)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Physical function test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in transcriptional profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success Rate (Supplemental Medication)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success Rate (Conversion to General Anesthesia)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Irritability Subscale of the Aberrant Behavior Checklist
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in tumor blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction in permeability of vessels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of flashbacks recorded
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HI antibody Neutralization antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: change from baseline in Quality of Recovery (QoR)-15 score after surgery
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: pain score on arrival to Post-Anesthesia Care Unit (PACU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urgent care events
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Artifacts in MRI images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vessel detectability in MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in glucose transporter expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Performance in Dictator game
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Performance in stag hunt game
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Number of Pertussis Cases
Endpoint domain: Mortality/survival
Primary endpoint: Episodes of ventricular fibrillation or ventricular tachycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Level of CD4+CD25high T Lymphocyte Regulatory Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: State of dyspnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined end-point
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intracompartmental pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morning fatigue severity
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Evening fatigue severity
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Lack of energy - frequency
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Dwell time difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bite size difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physician Assessment of Spasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Quality of life related to eating disorders
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Subjective Drug Value (SDV)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Bipolar Drug Liking VAS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Addiction Research Centre Inventory (ARCI) MBG
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Boston Carpal Tunnel Syndrome Questionnaire (BCTQ) functional score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Visual analog pain scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Disability of the Arm Shoulder Hand DASH
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Plasma Concentration of Active GLP-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Plasma Concentration of Total GLP-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Plasma Concentration of Total GIP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in AUC of Active GLP-1, Total GLP-1 and Total GIP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Gingival Margin Location
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Bone turnover markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Bone mineral density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Pharmacokinetics of lopinavir/ritonavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: headache and associated symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood flow velocity of the middle cerebral artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: diameter of the superficial temporal artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Prediction rate of Nivolumab Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum taurine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum ionized calcium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Hyperpigmentation of the Face
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Value of joint inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Extent of exposure
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Sexual function as measured by the IIEF Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: Changes in HCV viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients needing a third dose of antivenom
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients needing a blood transfusion
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients dying
Endpoint domain: Mortality/survival
Primary endpoint: Changes in endothelial function as evaluated by the flow-mediated dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in the arterial stiffness as evaluated by the peak wave velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in the clinical blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients who are progression-free
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of adverse events grade 3 or higher
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with anterior chamber cell ACC grade of zero
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Time spent with plasma glucose concentration in target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in KDIGO stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cardio-ankle vascular index (CAVI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Time to plasma glucose recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Need for a second adjustment time
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Largest external antero-posterior diameter of the sub-renal abdominal aorta
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Reduction in number of open fistulae
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With an Adverse Event (AE) During the Neoadjuvant Pembrolizumab Regimen
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Discontinued Treatment Due to an Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Treated With Neoadjuvant Pembrolizumab With a 2-fold or Greater Change From Baseline in Intratumoral CD3+ Lymphocytic Infiltration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Occurrence of fever > 38.5°C
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerability of transition from sildenafil to tadalafil
Endpoint domain: Adverse events/effects
Primary endpoint: Detection of Chlamydia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Frequency of All HAE Attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of risk factors for migraine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients remaining on ATV-based treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change from baseline in 24-hour UPE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Participants With Local and Systemic Adverse Events in Year One
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Local and Systemic Adverse Events in Year Two
Endpoint domain: Adverse events/effects
Primary endpoint: Resting State Functional Activity Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Continuous Performance Test of Attention (Median Reaction Time)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VE-cadherin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum lipid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of subjects with any dose limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: incidence rate of peripheral neuropathy
Endpoint domain: Adverse events/effects
Primary endpoint: BICR-Assessed Objective Response Rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skeletal muscle loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of External-beam PBI
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Severe Uterine Bleed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Non-sedentary time during leisure
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in the choice to self-administer alcohol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diffuse noxious inhibitory control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score obtained at the Rey figure test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Subject assessment of comfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Subject assessment of compliance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of patients readmitted
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Success of the conjoined twin separation surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Cohort Retention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Local and systemic reactions to injection
Endpoint domain: Adverse events/effects
Primary endpoint: Change in cognitive functioning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Proportion of Days Covered (PDC)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Postoperative quality of recovery score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Total IPSS Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of participants intending to undergo or having completed genetic testing
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of participants with rheumatoid arthritis flares
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of participants with reported physical injuries
Endpoint domain: Adverse events/effects
Primary endpoint: Brain activity during visuo-spatial attention tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood level of NTproBNP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of Treatment Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Seroprotected Subjects Against Diphtheria and Tetanus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Seropositive Subjects for Anti-pertussis Toxoid, Anti-pertactin and Anti-filamentous Haemagglutinin Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Booster Responders to Pertussis Toxoid, Filamentous Haemagglutinin and Pertactin Antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tumor Volume Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Binocular posture status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Life-threatening and Major Bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Conners 3rd Edition - Parent
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Social Responsiveness Scale (SRS)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Aberrant Behaviour Checklist (ABC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline QTcF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postoperative Care Unit (PACU) Recovery Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of eligible participants recruited
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of participants who complete the Faces Pain Scale-Revised
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants who complete at least 12 of 15 Liberi Exergame Sessions
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of patients with HbA1c below 7.0%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety of anti-CD19 allo CAR-T cells
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of anti-CD19 allo CAR-T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: LVEDVi
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: LVESVi
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency/nature of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in ECG patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in clinical laboratory parameters (including liver function tests)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum tolerated dose (MTD) of AMG 208
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical responses associated with AMG 208 treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety and tolerability of AMG 208
Endpoint domain: Adverse events/effects
Primary endpoint: Change of Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Suicidality assessment
Endpoint domain: Adverse events/effects
Primary endpoint: Number of serious adverse events per patient
Endpoint domain: Adverse events/effects
Primary endpoint: composite event
Endpoint domain: Mortality/survival
Primary endpoint: diagnostic values of skin prick-test and sIgE to almond
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Vineland Adaptive Behavior Scales, 3rd Edition
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cmax (Maximum Plasma Concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax (Time to Reach Maximum Plasma Concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast (Area Under the Plasma Concentration-time Profile From Time Zero to the Last Quantifiable Time Point Post-dose)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with oral mucositis
Endpoint domain: Adverse events/effects
Primary endpoint: HbA1c Change From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Platelet Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: diagnostic accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Employed in Competitive Integrative Employment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Percentage of Heavy Drinking Days
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Number of Infection-related Total Admitted Hospital Days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in beta-cell function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Condylar twist angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posterior condylar angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Plasma Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Oxypurinol Renal Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percent Change Uric Acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lipolytic activity (FFA AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: overnight glucose control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adherence to cardiovascular rehabilitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of HPV 6/11/16/18-related Cervical Intraepithelial Neoplasia (CIN)(Any Grade), Adenocarcinoma In Situ (AIS) or Cervical Cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of HPV 6/11/16/18-related External Genital Lesions (EGL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Asthma Symptom Perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pain Intensity
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in Pain Interference
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Validation of Arabic version CARIES-QC questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Carotenoids absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of unplanned analgesia interventions
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Anti-recombinant Thrombin Product Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Urinary continence proportion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: incidence of hypothermia
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of Fuzheng Huayu Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of Fuzheng Huayu Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes